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escalation thresholds influences predicted costs and quality adjusted life expec-
tancy (QALE) in T2DM economic evaluations. Methods: This study used the IMS 
Core Diabetes Model (CDM), a validated and established diabetes model, to evaluate 
the cost effectiveness of metformin+ sulphonylurea (M+S) compared to metformin 
+ DPP-4 (M+D). Baseline HbA1c was set to 8.0% (non-sampled scenario) with stand-
ard error of 0.8 (sampled scenario). Efficacy data for dual therapy was sourced from a 
published systematic review; HbA1c and BMI changes of -0.8% and 0.199kg/m2 (M+D) 
and -0.79% and 0.707kg/m2 (M+S) respectively were applied. Insulin rescue therapy 
was applied to both arms at HbA1c thresholds of 6.5%, 7.0% 7.5%. The model was 
run over a lifetime and costs (US$) and benefits were discounted at 3.5%. Results: 
Total incremental costs were $7,667, $9,571 and $11,644 for M+D versus M+S using 
sampled baseline HbA1c for therapy escalation thresholds of 6.5%, 7.0% 7.5% respec-
tively; and were $5,258, $2311 and $206 lower using non-sampled values, respec-
tively. A similar pattern was observed for QALE, in which incremental QALE gains 
were 85%, 42% and 1% lower with non-sampled compared to sampled baseline 
HbA1c for escalation thresholds of 6.5%, 7.0% 7.5% respectively. ConClusions: 
The importance of probabilistic analysis within cost effectiveness models extends 
beyond quantifying the effects of parameter uncertainty. When treatment decision 
rules are dependent on patient attributes that are subject to variability (such as 
HbA1c) then failing to accommodate this within the model can significantly bias 
predicted costs and QALE.
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objeCtives: This study aims at reviewing structural differences in Markov Models 
comparing different treatment strategies for Non-Metastatic Prostate Cancer related 
to scope, time-horizon, perspective, assumptions and the selection of parameters 
for the model. Methods: There is an abundant literature on Prostate Cancer. There 
are however few well performed RCT’s comparing different options for management 
for NMPCa.[1] Due to the lack of conclusive clinical evidence on the best treatment 
for localised prostate there has been a considerable interest in the modelling of 
prostate cancer in decision analytic models and economic evaluation.[2] The lit-
erature review in this paper focuses on the limited number of papers on economic 
evaluation related to the condition. In addition there are several articles presenting 
Markov Models. The evaluation was based on selected items from “Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS)”. Results: In NMPCa 
there are Markov models ranging from two to five health states [9]. The choice of 
model originates from the underlying assumptions, the aim/scope of the study or 
the availability of data to feed into the model. The insufficient clinical evidence 
and few preference based studies of health state values where the most influen-
tial elements in structuring the models Little attention is paid to the structural 
differences in the analysis and the discussions in the available papers. Structural 
uncertainty is viewed as external to the model and difficult to evaluate unless the 
structural choices are made transparent.[10]. ConClusions: Models in NMPCa 
differ in complexity and structure. The ability to evaluate the use of different models 
is highly dependent on transparency in the different building blocks. The CHEERS 
framework provided a useful tool in the evaluation input factors and the different 
Markov Model structures,
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objeCtives: Particularly in the context of HTA evaluations where both post-mar-
keting and pre-marketing data may be considered, the evidence to be synthesized 
can be sparse, partial and heterogeneous for safety outcomes. The Bayesian option 
has increasingly appeared as an unrivalled option for such challenging evidence 
synthesis cases but implementation in practice may be questioned. This work aims 
at determining how Bayesian meta-analysis or mixed treatment comparison of 
safety data can be optimized especially regarding the choice of prior distributions 
and model parameterization. Methods: Based on the latest developments from 
the DIA working group on Bayesian methods for safety data applied to specific 
real-world cases of both direct meta-analysis and mixed treatment comparisons 
(MTC), different model parameterizations and different forms of informative and 
non-informative prior distributions are tested, with various weights allocated to the 
clinical data vs. the observational information. Results: As opposed to the NICE 
parameterization of network meta-analysis, the 2-way predictor parameterization 
of MTC as proposed by the DIA working group provides more robust analysis based 
on non-informative priors. In the case of informative prior results, the most robust 
option was seen for equal total weight of clinical vs. observational data. Results 
of all meta-analyses appeared to be consistent across different model and prior 
specifications, even with low number of studies (< 10). ConClusions: Bayesian evi-
dence synthesis can leverage all available information in a robust manner for both 
direct and indirect comparisons, with fair quantification of uncertainty. Specific 
guidance on MTC model parameterization for safety data could complement the 
current NICE guidelines.
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objeCtives: To analyse the half-cycle correction and its effect on the final results 
of Markov models. Methods: In our analysis we focus on the half-cycle correction, 
which is a method used to deal with the inaccuracy caused by inadequate cycle 
marised recommendations on appropriate evidence sources for different model 
parameters in a narrative manner. Additionally, information on advantages and 
disadvantages of sources, on evidence identification methods and on data quality 
issues was extracted. Results: Twenty-eight documents fulfilled our inclusion 
criteria. We identified a large variety of evidence sources for informing model 
parameters on clinical effect size, natural history of disease, resource use, unit 
costs and health state utility values. They comprise research and non-research 
based sources. The documents do not provide structured advice on the hierarchy 
of evidence and on the limitations of evidence sources. The information is pre-
sented fragmentarily and is not tailored to specific model types. ConClusions: 
The usability of guidelines and manuals for modelling could be improved by 
addressing the issue of appropriate evidence sources in a more structured and 
comprehensive format.
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objeCtives: When the appropriate time horizon exceeds the evidence time 
horizon in a cost-effectiveness decision model, numerous uncertainties arise. 
One potential source of uncertainty is that of a possible future event that may 
affect one or more model parameters, e.g. a price shock or the emergence of 
a new comparator. These uncertain future events (UFEs) are rarely accounted 
for in health technology assessment and there is a dearth of guidance regard-
ing how they should be modelled. The objective of this study is to describe the 
circumstances under which UFEs could meaningfully impact cost-effectiveness 
estimates and to explore and demonstrate appropriate modelling techniques 
using a motivating example. Methods: Drawing on examples from HTA and 
other relevant literature, a framework is proposed to outline: when to take 
explicit account of uncertain future events for the purposes of reimbursement 
decisions, how different future events may affect value-of-information analysis 
and what modelling methods are likely to be useful when incorporating UFEs. 
Taking the example of a decision model seeking to estimate the cost-effective-
ness of an early interventional strategy for patients with non-ST-elevation acute 
coronary syndrome, a future price change is simulated and the framework is 
applied. Results: UFEs are shown to impact ‘accept or reject’ reimbursement 
decisions only in very specific circumstances where there is the potential to 
incur irrecoverable costs, whereas their role in value-of-information analysis is 
invariable. The applied example shows that the reimbursement recommenda-
tion for future populations may change with the occurrence of the future event 
and that there is value in reducing the uncertainty regarding the nature of the 
future event. ConClusions: UFEs will only impact expected costs-effectiveness 
sunder specific and rare circumstances. When it is appropriate to include a future 
event in a decision model, the uncertainty surrounding its likelihood, timing and 
magnitude should also be quantified.
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objeCtives: Modelling for cost-effectiveness studies often relies upon the use of 
spreadsheets. However, research has shown that approximately 90% of spread-
sheets contain technical errors. Furthermore, cost-effectiveness models rely on 
accurate transcription between many data sources, which increases the risk of 
errors further. The objective of this analysis was to ascertain the incidence of 
reported technical errors in cost-effectiveness models submitted to NICE as part of 
the Single Technology Assessment (STA) programme, which are subject to rigorous 
assessment by Evidence Review Groups (ERGs). Methods: NICE guidance docu-
ments were searched for a wide range of technical error types using the HTAinsite 
database. Reports were included if the ERG had identified technical errors in the 
manufacturer’s submission and this had been noted at committee level. Included 
appraisals were analysed to identify categories of errors identified. Results: Of 
the 102 completed STA Guidance documents searched, 39 appraisals met the inclu-
sion criteria of the study, representing a technical error incidence of 38.2% (95% CI: 
28.8 – 48.4%). Within these studies, 47 errors were identified in the following areas: 
computation (47%), logic (17%), transcription (13%) and data handling (9%). Error 
causes could not be determined in 15% of cases. The magnitude of effect caused by 
technical errors was difficult to determine, because corrected models often include 
additional changes to parameters or model structure. ConClusions: The inci-
dence of technical errors identified in the STA programme was lower than has 
previously been observed in studies of spreadsheet validity although this analysis 
assumes that ERG groups will identify all technical errors. The true incidence of 
errors may be higher than reported by this analysis. Use of best-practice methods 
and increased awareness of the causes and identification of technical errors may 
help to reduce their pervasiveness.
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objeCtives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
patients inevitably require therapy escalation or intensification. In health economic 
analyses, sampling input parameters is routinely undertaken for probabilistic analy-
sis but non-sampled analysis (mean values) is still commonplace. The objective of 
this study was to assess how sampling baseline HbA1c in combination with therapy 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A593
to assess the cost effectiveness of CML interventions were identified in MEDLINE 
and EMBASE. The studies were reviewed to map the method employed, how and why 
these approaches were selected, and lessons learned by the authors. Results: A 
total of unique CML models were reviewed. The large majority of these models were 
published in the last 10 years, with almost half being published in 2011. All but 1 of 
the models adopted a Markov structure, based around the following health states: 
chronic phase; accelerated phase; blast phase; and death. In line with best practice 
recommendations, over 75% of studies modeled progression and survival based on 
response to treatment. Extrapolation of trial data used a wide range of statistical 
models. Contrary to best practice recommendations, the fit of these models to the 
trial data and the validity of the extrapolation were not always tested. A variety of 
approaches were employed to estimate the health related quality of life associate 
with health states, including the direct valuation of health states, the use of stand-
ard health instruments (such as EQ5D), and mapping methods. ConClusions: 
Several approaches to the economic modeling of CML interventions were identified 
in the literature. A number of examples of good practice were identified, including 
the use of disease response outcomes when modeling progression and survival, and 
the systematic testing of the fit of survival distributions to trial data. Key challenges 
facing CML modeling are the validity of extrapolations of trial data given the long 
time periods over which these extrapolations are required, and the lack of data 
against which to validate them.
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objeCtives: The literature provides little guidance on statistical methods for esti-
mating parameters of Markov models using longitudinal data. We compared the 
commonly used naïve (based on raw data) and advanced approaches to estimate 
two model parameters: transition probabilities and hospitalisation rates. Both 
the naïve and advanced approaches were applied using data from the European 
Schizophrenia Cohort (EuroSC) to populate a Markov model in schizophre-
nia. Methods: EuroSC is a 2-year observational study of patients with schizo-
phrenia (n= 1,208), with 5 visits at 6-month intervals. Patients were classified into 
8 health states at each visit according to severity of symptoms assessed using the 
Positive and Negative Syndrome Scale (PANSS). For each health state, both model 
parameters (hospitalisation days and transition probabilities) were estimated 
based on raw data by pooling all time intervals (i.e. naïve approach). Similarly, 
for advanced methods, transition probabilities were estimated using multi-state 
models while hospitalisation days were estimated using two-part Generalised 
Estimating Equations (GEEs). Advanced methods adjusted for patient character-
istics and included random effects to account for repeated measures. Results: 
The naïve approach showed that the average number of hospitalisation days in 
a 6-month interval ranged from 4.20 in health state 1 to 19.43 in health state 8. 
Results from the two-part GEEs provided a range from 4.21 in health state 1 to 
14.7 in health state 8. GEEs tended to provide narrower confidence intervals. With 
regards to transition probabilities, differences between the naïve approach and the 
multi-state model were mostly seen in the second decimal place. ConClusions: 
While the naïve approach is frequently used for its simplicity, it has a number of 
shortcomings including: not accounting for repeated measures and not allowing 
for adjustment of patient characteristics. To increase the robustness of results, we 
recommend using statistical models that recognise and account for the unique 
distributional characteristics of data.
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objeCtives: Recent ISPOR Good practice guidelines as well as literature encourage 
to use a single distribution rather than the latent failure approach to model time to 
event for patient level simulation models with multiple competing outcomes. Aim 
was to apply the preferred method of a single distribution on time to event in combi-
nation with a multinomial distribution on type of event for parameterizing the pri-
mary tumor component of a patient level head and neck cancer model. Methods: 
Data on patients treated with radiation therapy as first line therapy for head and 
neck tumor at two university hospitals in The Netherlands between 25-02-1980– 
13-12-2010 was used (nUMCG= 277 & nVUMC= 736). Several distributions were 
tested for model fit, using QQ-plots, AIC, and simulated versus actual data plots 
to judge best fit. Covariates tested for inclusion were age, gender, tumor location 
dummies, nstage and tstage. The final model was applied in the patient simulation 
model. Multinomial regression with the same covariates and time of event added 
as a covariate was applied on type of event, distinguishing death, loco regional 
recurrence and metastasis as events. All analyses were performed in R. Results: 
The LogNormal distribution showed best fit. The final model had the following 
coefficients for the location parameter (se in brackets): Intercept, 8.2 (0.38), Age 
-0.026 (0.0053), Tstage -0.38 ( 0.062), Nstage -0.21 (0.076), Locd1 -0.91 (0.22) , Locd2 
-0.28 (0.15), Locd3 -0.72 (0.22). Locd refers to location dummies. The estimated 
value for Log(sd) was -0.44 (0.038). The multinomial model had age, tstage and 
time of event as significant covariates ConClusions: A disadvantage of this 
method is that a single distribution has to be fit to a time of event which is the 
result of different interacting stochastic processes. The resulting distributions 
showed acceptable fit and could be implemented straightforwardly in the patient 
level simulation model.
length in Markov models. The benefits of half-cycle correction has been widely 
published in the international literature. We measured the importance of half-cycle 
correction in the models submitted to the Hungarian HTA Office. We examined 
when it is adequate to use half-cycle correction and how big role should it have in 
the process of modelling. Results: Our experience shows that only 11% of the sub-
mitted models incorporated half-cycle correction. In more than half of these cases 
the value of the incremental cost-effectiveness ratio (ICER) changed by less than 1% 
when half-cycle correction was used compared to the base-case scenario. We also 
found the possibility that in some cases the added benefit of half-cycle correction 
is not considerable. ConClusions: The necessity of using half-cycle correction is 
essential in models, when the cycle length is half year or longer and if the number 
of the cycles of the models is less than 200. In most cases the half-cycle correction 
results in only a little change in the cost-effectiveness ratio of the submitted models, 
therefore half-cycle correction should be executed carefully.
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objeCtives: Randomized controlled clinical trials are the gold standard for deter-
mining causal inference. However, trials are expensive, and the results can be 
difficult to interpret. Our objective was to evaluate methods for clinical trial simu-
lation to understand how the simulation approach can be used for improved trial 
planning and interpretation of trial results. Our primary focus was trials of type 2 
diabetes and cardiovascular disease. Methods: We systematically searched the 
MEDLINE database for clinical trial simulation studies. We used the MeSH terms: 
Markov model, Markov chains, simulation, simulation model, microsimulation, 
computer model, and required type 2 diabetes mellitus and cardiovascular dis-
eases. We restricted the search to studies of humans published in English and 
found 92 publications. We also considered innovative clinical trial simulation 
methods from other areas to gain context. Results: A number of established 
techniques — notably, the Archimedes Model, Markov models, and observational 
analyses— are used for clinical trial simulation. Markov model-based simulations 
are widely employed, but have structural limitations with regard to the physiologi-
cal detail they can capture (e.g. multiple comorbidities). Retrospective, observa-
tional methods for clinical trial simulation are gaining utility as more databases 
become available. However, observational methods remain vulnerable to unknown 
biases. Finally, large-scale simulation models (such as the Archimedes model), with 
physiological underpinnings, provide accurate and clinically detailed trial simula-
tions. These models are used to simulate trials of therapies not yet marketed, or to 
forecast late stage trials. Model-based simulations require validations to ensure 
accuracy. ConClusions: Clinical trial simulation is an increasingly powerful 
tool, complementing real-world clinical trials. Large scale simulation modeling 
has been shown to be valuable for estimating and interpreting clinical findings. 
Recent studies suggest that future developments will leverage both large-scale 
simulation models and increasingly rich real-world evidence.
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objeCtives: New treatments registered in mCRPC are expected to alter the way 
patients are currently treated. It is hence essential for developers of any new treat-
ment not only to position it within the current therapeutic landscape, but also to 
anticipate what this landscape will resemble at time of launch. To address this issue, 
we developed a modeling tool that recast a new treatment’s value into the evolving 
therapeutic landscape. Methods: We conducted a literature review of existing 
health economic models in mCRPC, including recent HTA reports and conference 
abstracts. Technical and contextual elements were leveraged to build a flexible pro-
totype economic model for new treatments. The model encompasses disease man-
agement from asymptomatic mCRPC to patient’s death. It aims at describing the 
future management of mCRPC in including the current way patients are treated and 
the following innovative features: flexibility to alter the target population definition 
and size and to add new therapies. New therapies’ effectiveness and their expected 
positioning within the treatment pathway of mCRPC patients are assessed through 
the model. Results: We have created a dynamic prototype model to position new 
options in the current and future therapeutic landscape for treatment of mCRPC 
in Europe. Economic models identified in literature were addressing specific reim-
bursement questions and were not flexible enough to be re-used for our purpose of 
assessing therapeutic landscape evolution. However, some technical elements on 
costs and effectiveness could be leveraged for our model. The tool itself enabled to 
identify information gaps: epidemiology and real-life data were missing for some 
new treatments. These could be simulated and introduced in our easily-actualizable 
tool. ConClusions: An actualizable modeling and simulation tool was developed 
in mCRPC. This tool enables dynamic identification of the best public health and 
economic outcomes out of a new potential therapeutic alternative.
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objeCtives: To describe the methods adopted by economic models of CML inter-
ventions, assess their strengths and limitations, and develop best practice recom-
mendations. Methods: Examples of different economic modeling approaches used 
